Get the Stockscreener App
1.44
3.36%
-0.05
After Hours:
1.44
Biomea Fusion Inc stock is traded at $1.44, with a volume of 542.98K.
It is down -3.36% in the last 24 hours and down -34.55% over the past month.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
See More
Previous Close:
$1.49
Open:
$1.45
24h Volume:
542.98K
Relative Volume:
0.78
Market Cap:
$54.10M
Revenue:
-
Net Income/Loss:
$-144.01M
P/E Ratio:
-0.3591
EPS:
-4.01
Net Cash Flow:
$-113.02M
1W Performance:
-2.70%
1M Performance:
-34.55%
6M Performance:
-80.11%
1Y Performance:
-86.23%
1-Day Range:
$1.41
$1.52
1-Week Range:
$1.2905
$1.52
52-Week Range:
$1.2905
$13.07
Biomea Fusion Inc Stock (BMEA) Company Profile
Name
Biomea Fusion Inc
Sector
Industry
Phone
(650) 980-9099
Address
900 MIDDLEFIELD ROAD, REDWOOD CITY
Compare BMEA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.44 | 55.61M | 0 | -144.01M | -113.02M | -4.01 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-24 | Initiated | Edward Jones | Buy |
| Sep-27-24 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Sep-27-24 | Upgrade | Truist | Hold → Buy |
| Aug-29-24 | Initiated | CapitalOne | Overweight |
| Jun-11-24 | Downgrade | Truist | Buy → Hold |
| Jun-07-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-24 | Initiated | Truist | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jun-26-23 | Downgrade | Jefferies | Buy → Hold |
| May-12-23 | Initiated | Barclays | Overweight |
| Mar-29-23 | Reiterated | Oppenheimer | Outperform |
| Mar-28-23 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-23 | Initiated | Citigroup | Buy |
| Jun-02-22 | Resumed | H.C. Wainwright | Buy |
| Jan-12-22 | Initiated | H.C. Wainwright | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| May-11-21 | Initiated | JP Morgan | Overweight |
| May-11-21 | Initiated | Jefferies | Buy |
| May-11-21 | Initiated | Piper Sandler | Overweight |
View All
Biomea Fusion Inc Stock (BMEA) Latest News
Northern Trust Corp Boosts Holdings in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
D. E. Shaw & Co. Inc. Acquires New Shares in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion stock hits 52-week low at $1.37 amid sharp decline - Investing.com India
Biomea Fusion (NASDAQ:BMEA) Earns “Buy” Rating from D. Boral Capital - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Recommendation of “Buy” by Analysts - Defense World
Biomea Fusion Focuses on Core Programs in Q1 2025 - TipRanks
Analyst Maintains Buy Rating on Biomea Fusion (BMEA) with $16 Pr - GuruFocus
Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia - The Manila Times
Biomea Fusion’s BMF-500 Selected for Poster Presentation at - GlobeNewswire
Biomea Fusion’s BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia - Nasdaq
Breakthrough Leukemia Drug BMF-500 Exceeds Survival Expectations in Hard-to-Treat Patients - Stock Titan
Barclays PLC Increases Holdings in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
HC Wainwright Issues Pessimistic Forecast for Biomea Fusion (NASDAQ:BMEA) Stock Price - Defense World
Biomea Fusion's Stock Plummets After Price Target Cut — Bearish Retail Traders Speculate Next Moves - NewsBreak: Local News & Alerts
Biomea Fusion stock target cut to $18 by H.C. Wainwright - Investing.com Nigeria
BMEA: HC Wainwright & Co. Adjusts Price Target for Biomea Fusion - GuruFocus
Biomea Fusion (BMEA) Receives Buy Rating from D. Boral Capital | - GuruFocus
Biomea Fusion (BMEA) Receives Buy Rating from D. Boral Capital | BMEA Stock News - GuruFocus
Biomea Fusion (BMEA) Price Target Reduced by H.C. Wainwright | B - GuruFocus
Biomea Fusion reports Q1 EPS (80c), consensus (60c) - TipRanks
Biomea Fusion (BMEA) Focuses on Strategic Growth and Pipeline Ad - GuruFocus
Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights - The Manila Times
Biomea Fusion, Inc. Implements Strategic Realignment to Focus on Core Diabetes Programs and Optimize Cash Runway - Nasdaq
Biomea Fusion Slashes Workforce by 35%, Shifts Focus to $200B Diabetes Market Opportunity - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Biomea Fusion (BMEA) Projected to Post Earnings on Thursday - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Shares Sold by Alliancebernstein L.P. - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Wellington Management Group LLP Invests $317,000 in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Reviewing Biomea Fusion (NASDAQ:BMEA) and Tango Therapeutics (NASDAQ:TNGX) - Defense World
Biomea Fusion’s SWOT analysis: diabetes drug progress lifts stock outlook By Investing.com - Investing.com Australia
Biomea Fusion's SWOT analysis: diabetes drug progress lifts stock outlook - Investing.com
Biomea Fusion stock hits 52-week low at $1.86 amid sharp decline - Investing.com Canada
IVEY PMI Reading Due Next Week in Canada - The Globe and Mail
Biomea Fusion stock hits 52-week low at $1.86 amid sharp decline By Investing.com - Investing.com South Africa
Biomea Fusion Inc Stock (BMEA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):